Ginkgo Bioworks Reaffirms 2026 Cash Burn Guidance and Announces Autonomous Lab Sale to Novo Nordisk
Ginkgo Bioworks (NYSE: DNA) has reaffirmed its financial guidance for 2026, projecting an annual cash burn between $125 million and $150 million. This guidance comes as the company continues its strategic transformation toward a business model centered on autonomous laboratory operations. In a significant milestone for this transition, Ginkgo announced its first sale of an autonomous lab to pharmaceutical giant Novo Nordisk. Management indicated that the shift toward automation is meeting internal objectives and represents a successful execution of their long-term structural pivot.
Topics: autonomous labs business transformation earnings call